Lisa Salvatore
0000-0003-3864-0719
236 papers found
Refreshing results…
6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
6060 KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
6115 VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)
6080 Reintroduction of FOLFOXIRI treatment in metastatic colorectal cancer patients progressed after first-line FOLFOXIRI
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5fu/Lv) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
Kras Codon 61, 146 and Braf V600e Mutations Predict Resistance to Cetuximab Plus Irinotecan in Kras Codon 12 and 13 Wild-Type Metastatic Colorectal Cancer
Bevacizumab (Bv) in Combination With Folfoxiri (Irinotecan, Oxaliplatin and Infusional 5fu/Lv) in Metastatic Colorectal Cancer (Mcrc): Updated Results of a Phase Ii Gono Trial
First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients
Folfoxiri (Irinotecan, Oxaliplatin, Infusional 5fu/Lv) vs Folfiri as First-Line Treatment of Metastatic Colorectal Cancer (Mcrc): Updated Results After 5 Years Follow Up and Risk-Stratified Analysis
Second-Line Treatments in Patients With Metastatic Colorectal Cancer Progressed After First-Line Folfoxiri
Braf V600e Mutation and Amphiregulin (Ar) Immunohistochemical Expression in the Prediction of Benefit From Cetuximab Plus Irinotecan in Kras Wildtype Metastatic Colorectal Cancer (Mcrc) Patients
PTEN expression and KRAS mutations in the prediction of benefit from cetuximab plus irinotecan in metastatic colorectal cancer
Genetic Modulation of the Let-7 Micro-Rna Binding to Kras 3 '-Untranslated Region (3 '-Utr) Impacts on Survival of Metastatic Colorectal Cancer (Mcrc) Patients (Pts) With Unresponsive Disease to Salvage Cetuximab-Irinotecan
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Missing publications? Search for publications with a matching author name.